On January 13, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Stock Code: 01541.HK) announced that the Phase Ib/II clinical trial of its PD-L1xVEGF bispecific antibody IMM2510 combined with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has completed the enrollment of its first patient. This marks another significant milestone in the rapid clinical advancement of IMM2510.

The board (the “Board”) of directors (“Directors”, and each a “Director”) of the Company is pleased to announce that the Company has initiated the Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient.

Dallas, Texas, and Shanghai, China, Sep. 16, 2024 – Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo